TY - JOUR
T1 - Anti-CD20-IL-21 fusokine
T2 - The tail wags the dog
AU - Ansell, Stephen M.
N1 - Publisher Copyright:
© 2017 by The American Society of Hematology.
PY - 2017/4/20
Y1 - 2017/4/20
N2 - In this issue of Blood, Bhatt et al have shown that fusing interleukin 21 (IL-21) to an anti-CD20 antibody results in a molecule that has superior antilymphoma activity than each of its individual components.1 They find that the fused IL-21 induces direct cytotoxicity to the lymphoma cells but also activates immune effector cells that enhance the efficacy of the anti-CD20 antibody. The addition of IL-21 to an anti-CD20 antibody to form an anti-CD20-IL-21 fusokine therefore provides enhanced activity in 2 ways: firstly, it increases cytotoxicity directly targeting the malignant cell, and secondly, it modulates and augments the anti-tumor immune response (see figure).
AB - In this issue of Blood, Bhatt et al have shown that fusing interleukin 21 (IL-21) to an anti-CD20 antibody results in a molecule that has superior antilymphoma activity than each of its individual components.1 They find that the fused IL-21 induces direct cytotoxicity to the lymphoma cells but also activates immune effector cells that enhance the efficacy of the anti-CD20 antibody. The addition of IL-21 to an anti-CD20 antibody to form an anti-CD20-IL-21 fusokine therefore provides enhanced activity in 2 ways: firstly, it increases cytotoxicity directly targeting the malignant cell, and secondly, it modulates and augments the anti-tumor immune response (see figure).
UR - http://www.scopus.com/inward/record.url?scp=85028307905&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028307905&partnerID=8YFLogxK
U2 - 10.1182/blood-2017-02-767541
DO - 10.1182/blood-2017-02-767541
M3 - Comment/debate
C2 - 28428235
AN - SCOPUS:85028307905
SN - 0006-4971
VL - 129
SP - 2209
EP - 2210
JO - Blood
JF - Blood
IS - 16
ER -